Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Expert Review of Clinical Pharmacology|May 8, 2014
Vedolizumab for the treatment of ulcerative colitisSvend T Rietdijk, Geert R D'HaensJournal of Digestive Diseases|February 20, 2013
Recent developments in the treatment of inflammatory bowel diseaseSvend T Rietdijk, Geert R D'HaensCurrent Opinion in Pharmacology|May 20, 2008
Sensing intracellular pathogens-NOD-like receptorsSvend T Rietdijk, Timothy Burwell, John Bertin, et al.Annual Review of Immunology|March 3, 2010
HMGB1 and RAGE in inflammation and cancerGary P Sims, Daniel C Rowe, Svend T Rietdijk, et al.Gastroenterology|May 12, 2005
In vivo generation of oligoclonal colitic CD4+ T-cell lines expressing a distinct T-cell receptor VbetaAna C Abadía-Molina, Atsushi Mizoguchi, William A Faubion, et al.Immunity|June 11, 2004
Induced reactivity of intestinal CD4(+) T cells with an epithelial cell lectin, galectin-4, contributes to exacerbation of intestinal inflammationAkira Hokama, Emiko Mizoguchi, Ken Sugimoto, et al.Digestive Diseases and Sciences|October 16, 2020
Impaired Quality of Working Life in Inflammatory Bowel Disease PatientsSara van Gennep, Nanne K H de Boer, Marieke E Gielen, et al.European Journal of Gastroenterology & Hepatology|May 20, 2021
Work productivity loss is determined by fatigue and reduced quality of life in employed inflammatory bowel disease patients: a prospective multicentre cohort studySara van Gennep, Marieke E Gielen, Svend T Rietdijk, et al.International Immunology|January 22, 2004
Blocking inducible co-stimulator in the absence of CD28 impairs Th1 and CD25+ regulatory T cells in murine colitisYpe P de Jong, Svend T Rietdijk, William A Faubion, et al.Inflammatory Bowel Diseases|May 8, 2020
High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD StudySara van Gennep, Sanne W Evers, Svend T Rietdijk, et al.Pageof 2